HOME › DRUGS › EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL
ACTIVE SUBSTANCE / INN

EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL

Brand name(s): Atripla, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan, Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva
EMA LISTED
WITHDRAWN
AUTHORISED
HIV Infections
ACTIVE SUBSTANCE
Efavirenz;Emtricitabine;Tenofovir Disoproxil
REGULATORS
EMA
SPONSORS / MAH
Mylan Pharmaceuticals Limited, Gilead Sciences Ireland UC, Zentiva k.s.
TOTAL APPLICATIONS
4
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
Efavirenz/Emtricitabine/Tenofovir disoproxil MylanMylan Pharmaceuticals LimitedAuthorised05/09/2017HIV Infections
Efavirenz/Emtricitabine/Tenofovir disoproxil ZentivaZentiva k.s.Authorised17/07/2017HIV Infections
Efavirenz/Emtricitabine/Tenofovir disoproxil KrkaKRKA, d.d., Novo mestoAuthorised08/02/2018HIV Infections
AtriplaGilead Sciences Ireland UCWithdrawn13/12/2007HIV Infections

FULL INTELLIGENCE ON EFAVIRENZ;EMTRICITABINE;TENOFOVIR DISOPROXIL

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →